Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRX211a for breakthrough cancer pain
ACTRN12625000898459Phase 2Not yet recruiting
- Sponsor
- InhaleRx
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of IRX211 in breakthrough cancer pain (BTcP) (2 arms), sponsored by InhaleRx. Primary endpoint: Efficacy of IRX211a in treating breakthrough pain episodes. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
IRX211
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on ACTRN12625000898459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000898459.